A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients

Tumor Associated Antigens (TAAs) are the privileged targets of almost all the cancer vaccines tested to date. Unfortunately all these vaccines failed to show a clinical efficacy. The main reason for this failure is the immune tolerance to TAAs that are self-proteins expressed by normal and cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallou, Catherine, Rougeot, Aude, Graff-Dubois, Stéphanie, Kosmatopoulos, Kostas, Menez-Jamet, Jeanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312321/
https://www.ncbi.nlm.nih.gov/pubmed/27506946
http://dx.doi.org/10.18632/oncotarget.11086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312321/
https://www.ncbi.nlm.nih.gov/pubmed/27506946
http://dx.doi.org/10.18632/oncotarget.11086

Ejemplares similares